Agilent Technologies, Inc. (A) Analyse boursière

Présentation de l'entreprise

Agilent Technologies, Inc. operates globally within the healthcare sector, specifically focusing on the diagnostics and research industry by providing application-focused solutions to life sciences, diagnostics, and applied chemical markets. The enterprise functions through three primary segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets, delivering specialized instrumentation and software to these critical verticals. This diversified operational structure supports a significant scale, evidenced by a market capitalization of $33.07B and an annualized revenue of $7.06B generated across its business units. The company employs approximately 18,000 individuals, indicating a substantial organizational footprint that allows for extensive R&D capabilities and global distribution networks. Such a market capitalization places the firm among the large-cap constituents of the healthcare equipment and services space, reflecting its established position as a major player in scientific instrumentation. The revenue figure of $7.06B suggests a robust business model capable of generating consistent cash flows from a diverse portfolio of products and services required by research laboratories and diagnostic facilities worldwide.

Santé financière

The company reported a trailing twelve-month revenue of $7.06B, with a net income of $1.29B and an EBITDA of $1.97B. The substantial gap between the $7.06B revenue and the $1.29B net income reveals a significant cost structure comprising operating expenses, cost of goods sold, taxes, and interest costs that consume more than half of the top-line revenue. Despite the lower net income, the EBITDA of $1.97B highlights the core profitability of operations before financing and non-cash items. The firm generated free cash flow of $855.88M, which provides substantial financial flexibility for capital expenditures, debt repayment, or potential strategic acquisitions without immediate reliance on external financing. Profitability metrics show a gross margin of 52.3%, indicating high pricing power and efficient manufacturing or sourcing relative to the cost of revenue. The operating margin stands at 22.9%, reflecting the efficiency of administrative and sales functions in converting revenue into operating profit, while the profit margin of 18.3% demonstrates the final return to shareholders after all expenses including taxes and interest. On the balance sheet, the company holds $1.76B in cash against $3.55B in debt, resulting in a debt-to-equity ratio of 51.39, which suggests a moderately leveraged position where debt usage exceeds equity capitalization. A current ratio of 2.07 indicates strong short-term liquidity, as the company holds more than twice the value of current liabilities in current assets. Furthermore, a return on equity of 19.9% and a return on assets of 8.5% reveal that management is effectively deploying shareholder capital and utilizing the asset base to generate returns that exceed the cost of capital.

Évaluation de la valorisation

Valuation multiples indicate a trailing P/E ratio of 25.87, while the forward P/E is projected at 17.76. The significant difference between the trailing and forward P/E implies that the market expects earnings growth in the future that would justify a lower multiple relative to current earnings, suggesting an anticipated improvement in profitability or a re-rating of the stock. The price-to-book ratio is 4.78, which indicates that the market values the company at a significant premium over its book value, reflecting intangible assets, brand strength, or growth expectations not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 4.68 and an EV/EBITDA of 17.67, which suggest the company is priced in line with high-growth peers or those with strong cash conversion capabilities despite current earnings volatility. Price action over the last year shows a 52-week high of $160.27 and a 52-week low of $96.43. Without the specific current share price provided in the available facts, the exact percentage deviation from the 52-week high cannot be calculated, but the range of $63.84 between the high and low demonstrates the stock's historical volatility within the year. The beta of 1.30 indicates that the stock price is generally more volatile than the broader market, moving approximately 30% more than the index during periods of market fluctuation.

Growth & Income

Recent performance data shows a revenue growth of 7.0% year-over-year, while earnings growth declined by -3.6% year-over-year. This divergence indicates that earnings are currently growing slower than revenue, which implies that operating leverage has not yet been fully realized or that cost pressures and one-time charges have impacted the bottom line more heavily than the top line. For dividend payers, the company offers a dividend yield of 0.9% with a payout ratio of 22.0%. The low payout ratio of 22.0% suggests that the dividend is highly sustainable given the company's earnings, as only a small fraction of net income is distributed to shareholders, leaving ample room for retention and reinvestment. Given the negative earnings growth, the payout ratio remains conservative, ensuring that dividends are paid well below the earnings threshold. Overall, the growth and income profile presents a scenario of stable revenue expansion paired with a temporary earnings contraction, supported by a highly conservative dividend policy that prioritizes capital preservation over aggressive shareholder payouts.